| Symbol | DWTX |
|---|---|
| Name | DOGWOOD THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 44 MILTON AVENUE, ALPHARETTA, Georgia, 30009, United States |
| Telephone | +1 866 620-8655 |
| Fax | — |
| — | |
| Website | https://www.virios.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001818844 |
| Description | Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. Additional info from NASDAQ: |
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Read moreDogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Read more(99% Neutral) DOGWOOD THERAPEUTICS, INC. (DWTX) Announces Regulatory Update
Read moreDe La Rosa Abel 🟢 acquired 16.8K shares (1 derivative) of Dogwood Therapeutics, Inc. (DWTX) at $1.50 Transaction Date: Jun 16, 2026 | Filing ID: 000001
Read moreThomas John C 🟢 acquired 16.8K shares (1 derivative) of Dogwood Therapeutics, Inc. (DWTX) at $1.50 Transaction Date: Jun 16, 2026 | Filing ID: 000002
Read moreWhitley Richard James 🟢 acquired 16.8K shares (1 derivative) of Dogwood Therapeutics, Inc. (DWTX) at $1.50 Transaction Date: Jun 16, 2026 | Filing ID: 000002
Read moreKeefer David R 🟢 acquired 16.8K shares (1 derivative) of Dogwood Therapeutics, Inc. (DWTX) at $1.50 Transaction Date: Jun 16, 2026 | Filing ID: 000002
Read moreDogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Read moreNew Form SCHEDULE 13G - Dogwood Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002141 <b>Size:</b> 10 KB
Read more(30% Negative) DOGWOOD THERAPEUTICS, INC. (DWTX) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06848348 | Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced… | Phase2 | Chemotherapy Induced Neuropathic Pain | Recruiting | 2025-02-21 | 2026-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Halneuron (Open Label Extension) | Other | Phase PHASE2 | Chemotherapy Induced Neuropathic Pain | RECRUITING | NCT06848348 |
| Placebo | Other | Phase PHASE2 | Chemotherapy Induced Neuropathic Pain | RECRUITING | NCT06848348 |
| Halneuron | Other | Phase PHASE2 | Chemotherapy Induced Neuropathic Pain | RECRUITING | NCT06848348 |
| Placebo | Other | Phase PHASE2 | Chemotherapy Induced Neuropathic Pain | RECRUITING | NCT06848348 |
| Halneuron | Other | Phase PHASE2 | Chemotherapy Induced Neuropathic Pain | RECRUITING | NCT06848348 |
| Placebo | DRUG | Phase PHASE2 | Chemotherapy Induced Neuropathic Pain | RECRUITING | NCT06848348 |
| Halneuron | DRUG | Phase PHASE2 | Chemotherapy Induced Neuropathic Pain | RECRUITING | NCT06848348 |